Johnson & Johnson's HIV treatment Prezista reduced the amount of the virus to undetectable levels in 84% of patients, as compared with Abbott Laboratories' Kaletra, which lowered the amount in only 78% of patients, researchers report. However, such findings do not imply that Prezista should be recommended in place of Kaletra as a first-line protease inhibitor, a co-author of the study said.

Full Story:

Related Summaries